Do analysts prefer CNTN or SPRY?

ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 255.16%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to CNTN or SPRY?

In the previous week, ARS Pharmaceuticals had 10 more articles in the media than Hillstream Biopharma. MarketBeat recorded 12 mentions for ARS Pharmaceuticals and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.94 beat ARS Pharmaceuticals' score of 0.16 indicating that Hillstream Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZVRA or CNTN?

Zevra Therapeutics presently has a consensus target price of $29.29, suggesting a potential upside of 112.06%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Zevra Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ZVRA or CNTN?

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 2 articles in the media. Zevra Therapeutics' average media sentiment score of 0.94 equaled Hillstream Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CYRX or CNTN?

CryoPort presently has a consensus price target of $15.11, indicating a potential downside of 4.72%. Given CryoPort's stronger consensus rating and higher probable upside, research analysts plainly believe CryoPort is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CYRX or CNTN?

In the previous week, CryoPort had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for CryoPort and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.94 beat CryoPort's score of 0.88 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CNTN or ESPR?

Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 75.32%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Esperion Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CNTN or ESPR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Hillstream Biopharma. Esperion Therapeutics' average media sentiment score of 1.65 beat Hillstream Biopharma's score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend CNTN or ALLO?

Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 303.90%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69

Is CNTN or ALLO more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer CNTN or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Hillstream Biopharma. Allogene Therapeutics' average media sentiment score of 1.12 beat Hillstream Biopharma's score of 0.94 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hillstream Biopharma (CNTN) Competitors

$2.94 +0.12 (+4.26%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$2.99 +0.05 (+1.67%)

As of 06:37 AM Eastern

Compare

CNTN vs. SPRY, ZVRA, CYRX, ESPR, and ALLO

Should you buy Hillstream Biopharma stock or one of its competitors? MarketBeat compares Hillstream Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hillstream Biopharma include ARS Pharmaceuticals (SPRY), Zevra Therapeutics (ZVRA), CryoPort (CYRX), Esperion Therapeutics (ESPR), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Hillstream Biopharma compare to ARS Pharmaceuticals?

Hillstream Biopharma (NASDAQ:CNTN) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Hillstream Biopharma has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
ARS Pharmaceuticals	$84.28M	9.36	-$171.30M	-$2.01	N/A

In the previous week, ARS Pharmaceuticals had 10 more articles in the media than Hillstream Biopharma. MarketBeat recorded 12 mentions for ARS Pharmaceuticals and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.94 beat ARS Pharmaceuticals' score of 0.16 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 255.16%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hillstream Biopharma has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hillstream Biopharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Hillstream Biopharma's return on equity of -31.50% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

Hillstream Biopharma beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 2 articles in the media. Zevra Therapeutics' average media sentiment score of 0.94 equaled Hillstream Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.67	$83.23M	$1.99	6.94
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to Hillstream Biopharma's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Zevra Therapeutics presently has a consensus target price of $29.29, suggesting a potential upside of 112.06%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Zevra Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Zevra Therapeutics beats Hillstream Biopharma on 11 of the 13 factors compared between the two stocks.

How does Hillstream Biopharma compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

CryoPort has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.37	$78.30M	$1.35	11.75
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

In the previous week, CryoPort had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for CryoPort and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.94 beat CryoPort's score of 0.88 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort presently has a consensus price target of $15.11, indicating a potential downside of 4.72%. Given CryoPort's stronger consensus rating and higher probable upside, research analysts plainly believe CryoPort is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 10.0% of CryoPort shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CryoPort has a net margin of 41.57% compared to Hillstream Biopharma's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Hillstream Biopharma	N/A	-31.50%	-24.72%

CryoPort has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Summary

CryoPort beats Hillstream Biopharma on 14 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Esperion Therapeutics?

Hillstream Biopharma (NASDAQ:CNTN) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Esperion Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Hillstream Biopharma. Esperion Therapeutics' average media sentiment score of 1.65 beat Hillstream Biopharma's score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Esperion Therapeutics has higher revenue and earnings than Hillstream Biopharma. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 75.32%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Hillstream Biopharma's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Esperion Therapeutics beats Hillstream Biopharma on 12 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Allogene Therapeutics?

Hillstream Biopharma (NASDAQ:CNTN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hillstream Biopharma's return on equity of -31.50% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 303.90%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Allogene Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Hillstream Biopharma. Allogene Therapeutics' average media sentiment score of 1.12 beat Hillstream Biopharma's score of 0.94 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hillstream Biopharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Hillstream Biopharma has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Allogene Therapeutics	$20K	36,413.33	-$190.89M	-$0.77	N/A

Summary

Allogene Therapeutics beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$217.49M	$788.55M	$4.45B	$12.59B
Dividend Yield	N/A	4.84%	13.31%	6.14%
P/E Ratio	-2.56	1.52	23.55	25.27
Price / Sales	N/A	119.54	175.93	100.70
Price / Cash	N/A	20.06	37.25	59.26
Price / Book	0.27	8.17	15.26	6.62
Net Income	-$35.92M	-$3.96M	$114.87M	$336.83M
7 Day Performance	9.70%	4.37%	1.65%	3.25%
1 Month Performance	24.05%	2.80%	-2.37%	0.92%
1 Year Performance	N/A	53.25%	11.42%	27.62%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.4006 of 5 stars	$2.94 +4.3%	N/A	N/A	$217.49M	N/A	N/A	2	Gap Down
SPRY ARS Pharmaceuticals	3.4158 of 5 stars	$8.01 -6.4%	$28.20 +252.1%	-50.7%	$850.04M	$84.28M	N/A	90
ZVRA Zevra Therapeutics	4.54 of 5 stars	$14.34 +2.4%	$29.29 +104.2%	+54.3%	$828.20M	$106.47M	7.21	20
CYRX CryoPort	3.7725 of 5 stars	$15.70 -3.6%	$15.11 -3.8%	+117.0%	$820.55M	$176.18M	11.63	1,186	Positive News
ESPR Esperion Therapeutics	2.7785 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+216.0%	$811.73M	$403.14M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. SPRY, ZVRA, CYRX, ESPR, and ALLO

How does Hillstream Biopharma compare to ARS Pharmaceuticals?

Summary

How does Hillstream Biopharma compare to Zevra Therapeutics?

Summary

How does Hillstream Biopharma compare to CryoPort?

Summary

How does Hillstream Biopharma compare to Esperion Therapeutics?

Summary

How does Hillstream Biopharma compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. SPRY, ZVRA, CYRX, ESPR, and ALLO

How does Hillstream Biopharma compare to ARS Pharmaceuticals?

Which has stronger valuation and earnings, CNTN or SPRY?

Does the media refer more to CNTN or SPRY?

Do analysts prefer CNTN or SPRY?

Which has more risk & volatility, CNTN or SPRY?

Do insiders & institutionals have more ownership in CNTN or SPRY?

Is CNTN or SPRY more profitable?

Summary

How does Hillstream Biopharma compare to Zevra Therapeutics?

Does the media favor ZVRA or CNTN?

Which has more risk and volatility, ZVRA or CNTN?

Which has stronger earnings and valuation, ZVRA or CNTN?

Do insiders and institutionals hold more shares of ZVRA or CNTN?

Is ZVRA or CNTN more profitable?

Do analysts prefer ZVRA or CNTN?

Summary

How does Hillstream Biopharma compare to CryoPort?

Which has stronger valuation & earnings, CYRX or CNTN?

Does the media prefer CYRX or CNTN?

Do analysts recommend CYRX or CNTN?

Do insiders & institutionals have more ownership in CYRX or CNTN?

Is CYRX or CNTN more profitable?

Which has more risk and volatility, CYRX or CNTN?

Summary

How does Hillstream Biopharma compare to Esperion Therapeutics?

Does the media refer more to CNTN or ESPR?

Which has stronger valuation & earnings, CNTN or ESPR?

Do analysts recommend CNTN or ESPR?

Do insiders and institutionals have more ownership in CNTN or ESPR?

Which has more volatility and risk, CNTN or ESPR?

Is CNTN or ESPR more profitable?

Summary

How does Hillstream Biopharma compare to Allogene Therapeutics?

Do insiders & institutionals have more ownership in CNTN or ALLO?

Is CNTN or ALLO more profitable?

Do analysts recommend CNTN or ALLO?

Does the media prefer CNTN or ALLO?

Which has more volatility & risk, CNTN or ALLO?

Which has better earnings and valuation, CNTN or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools